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Abstract
We consider the feasibility of reusing existing control data obtained in genetic association studies in order to reduce costs
for new studies. We discuss controlling for the population differences between cases and controls that are implicit in studies
utilizing external control data. We give theoretical calculations of the statistical power of a test due to Bourgain et al (Am J
Human Genet 2003), applied to the problem of dealing with case-control differences in genetic ancestry related to
population isolation or population admixture. Theoretical results show that there may exist bounds for the non-centrality
parameter for a test of association that places limits on study power even if sample sizes can grow arbitrarily large. We apply
this method to data from a multi-center, geographically-diverse, genome-wide association study of breast cancer in African-
American women. Our analysis of these data shows that admixture proportions differ by center with the average fraction of
European admixture ranging from approximately 20% for participants from study sites in the Eastern United States to 25%
for participants from West Coast sites. However, these differences in average admixture fraction between sites are largely
counterbalanced by considerable diversity in individual admixture proportion within each study site. Our results suggest
that statistical correction for admixture differences is feasible for future studies of African-Americans, utilizing the existing
controls from the African-American Breast Cancer study, even if case ascertainment for the future studies is not balanced
over the same centers or regions that supplied the controls for the current study.
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Introduction
A genetic association study estimating the main effects of single
nucleotide polymorphisms (SNPs) or other genetic variants upon
the risk of a rare or common disease in minority populations is a
setting in which it is especially attractive to consider the use of
existing genotype data as a supplementary or even a primary
source of controls. DNA samples may be expensive and difficult to
PLoS Genetics | www.plosgenetics.org 1 September 2010 | Volume 6 | Issue 9 | e1001096obtain, and response rates are often lower in minority populations
[1]. Researchers might consider using an already available ‘‘stand
in’’ population sample as controls, provided that genotype
frequencies are equivalent to those in the population from which
controls would be drawn. There are however two immediate
concerns raised, one fundamental and the other technical in
nature: The fundamental question is whether or not the controls
are sampled from the same underlying population (or populations)
as are the cases – or more generally the feasibility and ‘‘cost’’
(generally loss of statistical power) of controlling for case/control
differences if they arise. The technical question is whether
differences in genotyping, including differences in DNA prepara-
tion, and in the actual markers genotyped in cases and controls,
i.e. when the platforms are not identical so that imputation is relied
upon to make up the difference, may introduce false positive (or
false negative) associations.
Consider the problem of conducting a genetic association study
aimed at discovering genetic variants related to the risk of a
disease, where there already exists extensive genotyping data,
perhaps publicly available, for members of similar populations. If
the disease under consideration is rare (so that genotype
frequencies for controls may be expected to be the same as in
the general population) then it is intuitively appealing to consider
using existing control data from studies of other rare diseases (or
population-based studies if they exist) to reduce the cost or increase
the statistical power of an association study. From the classical
case-control literature, a study that uses 1:m matching of controls
to each of n cases will be equivalent in power to a 1:1 matched
study with N~2n m
(1zm) cases (and an equal number of controls).
Thus a study with a large number of controls, m, for each case will
have nearly twice the effective sample size of a 1:1 matched study
[2].
Note that 1:m matched studies (with m.1) are only cost
effective if it is more costly or difficult to obtain additional cases
than it is to obtain additional suitable controls since the increment
in effective sample by (for example) doubling the number of case-
control pairs (in a 1:1 matching) is twice that of adding two new
controls to each existing pair (to achieve 1:3 matching) to a study
even though the total number of participants is the same. If
however the cost of adding an additional control is far less than
that of adding an additional case (because control data is already
available) then adding the almost ‘‘free’’ controls is highly
attractive although the returns diminish as more and more
controls are added, with the increment in effective sample size
governed by m/(m+1).
This paper considers these issues from both theoretical and
empirical perspectives. We apply a recent generalization [3–6] of
the testing procedure of Bourgain et al [7] to the situation where
population substructure (in the broad sense), including admixture
and relatedness between subjects, is estimated from marker data
rather than being assumed to be known as the basis for our
theoretical considerations of study power. We point out below the
relationship between this procedure and that of the more widely
known principal components technique [8]. Our empirical
investigation of the use of existing controls utilizes data from a
genome-wide association study (GWAS) of breast cancer in
African American women, namely the African American Breast
Cancer (AABC) study, in which cases and controls come from a
total of 9 different studies widely distributed geographically
throughout the United States. African Americans are a relatively
understudied group (compared to European Americans) in studies
of genetic susceptibility. African Americans are admixed with
Europeans and (in some cases) with Hispanics (themselves an
admixed group) and Native Americans [9,10]. We examine
empirically the false positive rates that occur when cases from one
geographical location or study within the AABC study are
combined with controls from other AABC locations or studies,
as well as the success (and cost in terms of loss of effective sample
size) of adjustment for the observed population differences in
global genetic ancestry when analyzing such illustrative data sets
derived from the AABC study.
Methods
Statistical Methods
We utilize an approach derived from that of Bourgain et al [7]
which has been discussed extensively in recent papers [3–5]. This
approach for accounting for relatedness between subjects in
association tests adopts a ‘‘retrospective’’ approach towards the
problem of testing for disease associations using marker data, in
which (as in the Armitage test) the allele frequency of a variant is
related to case-control status. In vector notation we have
Sj~(S1j,S2j,...,SNtotj)
T of observed values for a given SNP j.
Here Ntot is the total number of subjects (cases+controls) in the
study, and SNP values Sij are coded as (0,1,2) for the number of
copies of a specified allele, j, carried by subject i. (This coding of
SNP genotype implies that we are interested in additive models for
the relationship between disease risk and genotype but the
approach can readily be extended to other codings). The
retrospective approach models the mean of Sj as a function of
case-control status. If we define the Ntot|2 design matrix C to
have rows (1 ci) where ci is case-control status (0 or 1) for subject i
then the mean, mj,o fSj is written as
mj~Cbj with bj~ b1j, b2j
   T
Relatedness between subjects induces a covariance matrix for the
number of copies of a given SNP of form
Cov(Sj)~s2
j K ð1Þ
with s2
j specific to each SNP but with the same matrix K for all
Author Summary
This paper discusses and provides unique insight into an
important problem raised by the current state of genetic
studies into disease susceptibility, namely whether we can
reuse genetic data from participants genotyped as
controls in one study when cases (people with a disease
of interest) are obtained from other studies, or whether
each new study needs its own controls. We are interested
in whether studies where cases and controls are sampled
differently will give correct answers and are as powerful
statistically as when new control data is also genotyped.
Because of the huge investments made recently in large
scale genotyping of cases and controls for various
diseases, this is a timely question. This question is
especially important in understanding the genetic causes
of disease in as-yet relatively understudied population
groups, such as African-Americans, in order to speed up
progress when this is possible. We give theoretical results
about the power of studies that reuse existing control
genotypes based on statistical considerations. We also
provide analysis of real data from a major study of the
genetic causes of breast cancer in African-American
women in order to shed practical light upon this issue.
Reuse of Existing Genotype Data
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founders, this matrix K has diagonal elements equal to 1zhi
where hi is the inbreeding coefficient for subject i and each off-
diagonal element, Kij, is twice the kinship coefficient for the
relationship between subjects i and j [7].
It is worth noting that in general the topic of relatedness
includes what is often considered to be population substructure.
For example consider two large but isolated populations (freely
mixing within each population) that have been separated for many
generations. While a random sample of people from the same
population (with sample size small relative to the population size)
might be considered unrelated to each other when considering
that population separately, when considering the two populations
together people from one isolated population are considered to be
related to each other, relative to those in the other population. In
particular, genetic markers will, through a process of random drift
and other factors, be able to distinguish members from the two
populations, and this will be detectable when calculation of the K
matrix is performed. A standard method of simulating genetic
markers for divergent populations stemming from the same
ancestral population (e.g. the Balding-Nichols model [11]) can
readily be shown to produce covariance matrices of the form of
expression (1).
If K and s2
i are both known then the best linear unbiased
estimate (BLUE) of the regression vector bj is of weighted least
squares form
^ b bj ~(C
TK{1C)
{1C
TK{1Sj
and the variance covariance matrix of the estimates is in the form
of
Vj:Var(^ b bj)~s2
j (C
TK{1C)
{1
Thus inference on the significance of the allele frequency
difference between cases and controls may be based upon the
Wald test statistic
T2~(^ b b2j )
2=Vj½2,2  ð2Þ
with Vj½2,2  the (2,2) element of Vj
In general of course, K and s2
j are not known, except in the case
of known pedigrees and unrelated founders, where K can be
computed from first principles. The estimation of K using marker
data has been considered by a number of authors and both
method of moments [4,5] and maximum likelihood methods [3]
have been considered. A method of moments estimator of K can
be concisely written [5] as
^ K K~
1
M
X M
j~1
(Sj{2pj1)(Sj{2pj1)
T
4pj(1{pj)
ð3Þ
and the estimate of s2
j as
^ s s2
j ~1=(N{2)S
T
j ½K{1{K{1C(C
TK{1C)
{1C
TK{1 Sj
One value of this approach, which is exploited here, is that it is
relatively easy to compute the power of the Wald T2 test if we can
hypothesize a form of the relatedness matrix K. For a given form
for K (below we consider several forms for both isolated population
models and more complex admixed populations) then for a given
sample size, Ntot, a given allele frequency for a causal SNP, and a
hypothesized difference in allele frequencies between cases and
controls (which can then be related to odds ratios in typical case/
control analysis) we can compute the non-centrality parameter of
T2 (and hence the power of the test) as
l
2~(b2j )
2=Vj½2,2  ð4Þ
We illustrate the computation of this non-centrality parameter for
a number of important special cases in the results section below. It
is worth noting now, however, that the Bourgain test appears to be
reasonably powerful compared to other procedures, and can
sometimes be considered as a compromise between the principal
components method [8] and genomic control [12]. We attempt to
justify this last statement in the results section below.
In addition to the Bourgain test we used several well known
tools for addressing population structure in the AABC data. For
example we computed eigenvectors through the use of the
program EIGENSTRAT [8]. Briefly, each eigenvector explains
a proportion of the genetic variation among samples in the analysis
so that the leading eigenvector explains the greatest variation,
followed by the second eigenvector, and so forth. The full set of
eigenvectors form an orthonormal basis so that each eigenvector is
scaled on the unit interval and linearly independent from all other
eigenvectors. Note that the EIGENSTRAT procedure is operating
on the same estimated K matrix, ^ K K, that we have described above.
To assess ancestry within the AABC study in relation to
reference populations from HapMap, we performed a principal
components analysis based on ancestry informative markers that
were genotyped in both the AABC study and the HapMap Phase 3
populations. The 2,546 ancestry informative markers (contained
within the Illumina 1M genotyping array which was used in the
AABC scan) were selected based on low inter-marker correlation
and high correlation to a previously determined eigenvector that
explained African and European ancestry.
We quantified percent African ancestry for each of the nine
AABC study populations by running the program STRUCTURE
for each study population. The program implements a Markov
Chain Monte Carlo algorithm that provides the posterior
estimates of the proportion of ancestry from each of k clusters
for each individual, where k is specified by the investigator. For
each AABC study population, we assigned k=3, including
genotypes from the same ancestry informative markers used in
PCA genotyped in YRI, CEU, and JPT from HapMap Phase 3.
Studies in AABC
AABC included 9 epidemiological studies of breast cancer
among African American women, which comprise a total of 3,153
cases and 2,831 controls. Below is a brief description of these
studies.
The Multiethnic Cohort Study (MEC). The MEC is a
prospective cohort study of 215,000 men and women in Hawaii
and Los Angeles [1] between the ages of 45 and 75 years at
baseline (1993–1996). Through December, 31 2007, a nested
breast cancer case-control study in the MEC included 556 African
American cases (554 invasive and 12 in situ) and 1,003 African
American controls. An additional 178 African American breast
cancer cases (ages: 50–84) diagnosed between June 1, 2006 and
December 31, 2007 in Los Angeles County (but outside of the
MEC) were combined with the MEC samples in the analysis.
The Los Angeles component of The Women’s Con-
traceptive and Reproductive Experiences (CARE) Study.
The NICHD Women’s CARE Study is a large multi-center
Reuse of Existing Genotype Data
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effects of oral contraceptive (OC) use on invasive breast cancer risk
among African American women and white women ages35–64 years
in five U.S. locations [13]. Cases in Los Angeles County were
diagnosed from July 1, 1994 through April 30, 1998, and controls
were sampled by random-digit dialing (RDD) from the same
population and time period; 380 African American cases and 224
African American controls were included in stage 1 of the scan.
The Women’s Circle of Health Study (WCHS). The
WCHS is an ongoing case-control study of breast cancer among
women of European and African descent residing in the New York
City boroughs (Manhattan, the Bronx, Brooklyn and Queens) and
in seven counties in New Jersey (Bergen, Essex, Hudson, Mercer,
Middlesex, Passaic, and Union) [14]. Eligible cases included
women diagnosed with invasive breast cancer between 20 and 74
years of age; controls were identified through RDD. The WCHS
contributed 272 invasive African American cases and 240 African
American controls to stage 1 of the GWAS.
The San Francisco Bay Area Breast Cancer Study
(SFBC). The SFBC is a population-based case-control study of
invasive breast cancer in Hispanic, African American and non-
Hispanic White women conducted between 1995 and 2003 in the
San Francisco Bay Area [15]. African American cases, ages 35–79
years, were diagnosed between April 1, 1995 and April 30, 1999,
with controls identified through RDD. Stage 1 included 172
invasive African American cases and 231 African American
controls from SFBC.
The Northern California Breast Cancer Family Registry
(NC–BCFR). The NC-BCFR is an on-going population-based
family study conducted in the Greater San Francisco Bay Area,
and is one of 6 sites collaborating in the Breast Cancer Family
Registry (BCFR), an international consortium funded by NCI
[16]. African American breast cancer cases in NC-BCFR were
diagnosed after January 1, 1995 and between the ages of 18 and
64 years; population controls were identified through random digit
dialing (RDD). Stage 1 genotyping was conducted for 440 invasive
African American cases and 53 African American controls.
The Carolina Breast Cancer Study (CBCS). The CBCS is
a population-based case-control study conducted between 1993
and 2001 in 24 counties of central and eastern North Carolina
[17]. Cases were identified by rapid case ascertainment system in
cooperation with the North Carolina Central Cancer Registry and
controls were selected from the North Carolina Division of Motor
Vehicle and United States Health Care Financing Administration
beneficiary lists. Participants’ ages ranged from 20 to 74 years. For
stage 1, DNA samples were provided from 656 African American
cases with invasive breast cancer and 608 African American
controls.
The Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial (PLCO) Cohort. PLCO, coordinated by the
U.S. National Cancer Institute (NCI) in 10 U.S. centers, enrolled
during 1993–2001 approximately 155,000 men and women, aged
55–74 years, in a randomized, two-arm trial to evaluate the
efficacy of screening for these four cancers [18]. A total of 64
African American invasive breast cancer cases and 133 African
American controls contributed to stage 1 of the GWAS.
The Nashville Breast Health Study (NBHS). The NBHS is
a population-based case-control study of incident breast cancer
conducted in the Tennessee [19]. The study was initiated in 2001
to recruit patients with invasive breast cancer or ductal carcinoma
in situ, and controls, recruited through RDD between the ages of
25 and 75 years. NBHS contributed 310 African American
invasive cases (57 in situ), and 186 African American controls to
the stage 1 analysis.
Wake Forest University Breast Cancer Study (WFBC).
African American breast cancer cases and controls in WFBC were
recruited at Wake Forest University Health Sciences from
November 1998 through December 2008 [20]. Controls were
recruited from the patient population receiving routine
mammography at the Breast Screening and Diagnostic Center.
Age range of participants was 30–86 years. WFBC contributed
125 cases (116 invasive and 9 in situ) and 153 controls to the stage
1 analysis.
Genotyping
Genotyping in stage 1 was conducted using the Illumina
Human1M-Duo BeadChip. Of the 5,984 samples from these
studies (3,153 cases and 2,831 controls), we attempted genotyping
of 5,932, removing samples (n=52) with DNA concentrations
,20 ng/ul by pico green assay. After clustering the genotype data
we removed samples based on the following exclusion criteria: 1)
unknown replicates ($98.9% genetically identical) that we were
able to confirm (only one of each duplicate was removed, n=15);
2) unknown replicates that we were not able to confirm through
discussions with study investigators (pair or triplicate removed,
n=14); 3) samples with call rates ,95% after a second attempt
(n=100); 4) samples with #5% African ancestry (n=36)
(discussed below); and, 5) samples with ,15% mean heterozygos-
ity of SNPs in the X chromosome and/or similar mean allele
intensities of SNPs on the X and Y chromosomes (n=6) (these are
likely to be males).
In the analysis, we removed SNPs with ,95% call rate or minor
allele frequencies (MAFs) ,1%. To assess genotyping reproduc-
ibility we included 138 replicate samples; the average concordance
rate was 99.95% (.99.93% for all pairs). We also eliminated SNPs
with genotyping concordance rates ,98% based on the replicates.
The final analysis dataset included 3,016 cases and 2,745 controls,
with an average SNP call rate of 99.7% and average sample call
rate of 99.8%. Hardy-Weinberg equilibrium (HWE) was not used
as a criterion for removing SNPs for this analysis.
Results
Non-Centrality Parameter for the Bourgain Test in the
Case of Isolated Populations
We use the Balding Nichols model [11] for allele frequency
differences between isolated populations. In this model allele
frequencies for a SNP in modern data populations are distributed
according to a beta distribution B 1{F
F p, 1{F
F (1{p)
  
with p the
ancestral allele frequency of that SNP. In this model the variance
of the modern day allele frequency is Fp(1{p), thus F is a
parameter specifying the degree of separation between the modern
day and ancestral population. As described in Rakovski and Stram
2009 [4] if genotypes are obtained for randomly sampled
individual from two modern day isolated populations using this
model and the separation of each modern day population from the
ancestral population equals Fk (for k~1,2) statistic then the
covariance matrix, s2
j K between subjects for the jth SNP will have
diagonal terms equal to 2pj(1{pj)(1zF1) for members of the first
population, diagonal terms equal to 2pj(1{pj)(1zF2) for
members of the second, off diagonal terms of 4pj(1{pj)F1,
4pj(1{pj)F2, or zero for pairs of individuals who are either both
from the first population, both from the second population or from
different populations respectively. Here pj is the frequency in the
ancestral population of SNP j. Consider now a study in which all
cases come from one isolated population, and all controls from
another. Assume for simplicity that F1~F2~F (both populations
have the same degree of separation from their ancestral source),
Reuse of Existing Genotype Data
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that total sample size is 2N (the calculations below can be readily
altered for different matching fractions if necessary). Thus we can
write the variance of the estimator of the case-control difference
for SNP j as
Var(^ b bj)~s2
j (C
TK{1C)
{1
with the first column of C being a vector of 1’s and the second
column of C a vector of 1’s and 0’s indicating case-control (and
population) status. Using a readily derived formula for the inverse
of an N|N matrix of compound symmetric form
ab::: b
ba::: b
. .
. . .
.
P . .
.
bb::: a
2
6 6 6 6 6 4
3
7 7 7 7 7 5
{1
~
1
a2z(N{2)ab{(N{1)b2
az(N{2)b {b ::: {b
{ba z(N{2)b ::: {b
. .
. . .
.
P . .
.
{b {b ::: az(N{2)b
2
6 6 6 6
6 6 4
3
7 7 7 7
7 7 5
we can easily write
Var(^ b b2j)~2pj(1{pj)
4(N{2)Fz2
N
ð5Þ
Thus the non-centrality parameter, l
2 =b2j
2=Var(^ b b2j) of a test of
association does not increase linearly in N, but rather is bounded
above by the value
b2,j
2
8Fpj(1{pj)
. This can impose severe limi-
tations on the power of any study in which there are such
differences. To put this in perspective, consider two isolated
populations which are each separated from their ancestral
population with an F value of 0.0005, and consider an allele that
exhibits 40 percent frequency in the ancestral population. The
variance of the difference between the two isolated modern day
populations in the frequency of this allele is equal to 2pj(1{pj)F so
that we would expect by chance that there is a about a 1.5 percent
difference in allele frequencies between cases and controls for such
an allele. Consider now the detection, in a study of 5,000 cases and
5,000 controls, of a disease-causing allele of the same frequency
associated with a 10 percent difference in allele frequencies between
cases and controls (b2j =.2). The difference in allele frequencies is
approximately 6 times larger than expected due to population
differences, and can be seen to correspond to an odds ratio for
disease, under a multiplicative risk model, of 1.5 per copy of the risk
allele. From equation (2) the non-centrality parameter
b2j
2=Var(^ b b2j) will be equal to 34.73 in this case; on the other hand
if F between cases and controls is 0 the non-centrality parameter
will equal 208.33. Thus a study that would, given no differences
between cases and controls in population of origin, have
overwhelming power (..9999) to reject the null hypothesis at a
genome wide level significance (p,10{8) is, under this alternative,
reduced to having power of only 56 percent after correcting for the
differences in origins of cases and controls. The survey of European
populations by Nelis et al [21] estimates fixation indices, Fst, (which
can be equated to F under the Balding Nichols model) between
populations in SNP allele frequencies which range from less than
.001 between neighboring populations to 0.023 for Southern Italy
versus parts of Finland. Because our F values as defined above are
between present day and ancestral populations the fixation indices
calculated between present day populations by Nelis et al need to be
multiplied by K to be consistent with our definition of F. Thus the
example we have given (F~:0005) corresponds only to the nearest
neighbor populations in Europe and would appear to throw into
doubt any thought of using control data not perfectly matched in
ancestry to cases.
Admixed Populations
While the calculations given above appear to be pessimistic
regarding the usefulness of shared control data it is important to
note that the completely isolated population model is naı ¨ve and
makes assumptions not applicable to the study subjects for the
AABC study or indeed for most modern populations. Therefore we
broaden our discussion to admixed populations, specifically, when
the DNA from both cases and controls come from groups that are
admixed from the same two ancestral populations. We consider this
in two parts, first deriving results for comparisons between
‘‘completely’’ admixed populations, i.e. where the two populations
have different levels of admixture between the ancestral popula-
tions, but when there is no within-population heterogeneity in
ancestry. Next we focus on the much more realistic setting of
incompletely admixed populations serving as cases and controls.
Completely admixed populations. Here we consider each
of two populations of interest (one supplying cases and the other
controls) as consisting of randomly mating populations derived by
admixture from the same two ancestral populations. In the first
modern day population we assume that a1|100 percent of the
ancestors are from the first ancestral population and the remaining
(1{a1)|100 percent are from the other ancestral population.
In the second population the fractions are a2 and (1{a2)
respectively. We further assume that the two ancestral populations
are themselves derived from a single earlier ancestral population
and that the F values of these populations compared to the earlier
populations are both equal to the same value. Under these
simplifying assumptions (which can be readily relaxed if need be)
we can easily derive the covariance matrix for a SNP vector Sj
between subjects to have elements
Var(Sij)=2pj 1{pj
  
1zF 1z2a1
2{2a1
     
for subject i in
the first population (i.e. cases)
Cov(Sij,Skj)=4pj 1{pj
  
F 1z2a1
2{2a1
  
for both subjects i
and k in the first population
Var(Sij)=2pj 1{pj
  
1zF(1z2a2 a2{1 ðÞ ) ðÞ for subject i in
the second population (i.e. controls)
Cov(Sij,Skj)=4pj 1{pj
  
F 1z2a2
2{2a2
  
for both subjects i
and k in the second population and finally
Cov(Sij,Skj)=4pj 1{pj
  
F 1z2a1 a2{a1{a2 ðÞ for subjects i
and k in different populations
With sampling of N cases from the first modern day admixed
population and N controls from the second after repeated use of
the matrix formulae for the inverse of a compound symmetric
matrix we can compute the variance term for ^ b b2,j as the [2,2]
element of the variance covariance matrix, Var(^ b b),
Var(^ b b2,j)~s2
j (C
TK{1C){1
½2,2  ð6Þ
as
1
N
2pj(1{pj)|(2{2Fa1
2z4a1
2FN{8a1FNa2z2Fa1
{3Fz4Fa2{4Fa2
2z4FNa2
2zF(1z2a2
2{2a2))
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8pj(1{pj)F(a1{a2)
2.
We see that this bound is zero only if either F~0 or if a1~a2.
The non-centrality parameter will (as in the previous example)
then again be bounded from above. Consider for example two
groups of ‘‘completely’’ admixed modern-day subpopulations one
with 25 percent of ancestry from one ancestral population (and 75
percent from the other population) and the other with 20 percent
ancestry from the first ancestral population (and 80 percent from
the second). If we take the fixation index, Fst value of 0.153 of
Nelis et al for (applicable for HapMap Yorubans versus HapMap
Europeans) and the allele frequency and odds ratios as above (40
percent and 1.5 per copy respectively) then the non-centrality
parameter l
2~b2,j
2=Var(^ b b2,j) will be equal to 72.77 compared to
208.33 in the non-mixed case, leading again to loss of power
although not as extreme as in the previous example.
Incompletely admixed groups. The above example is still
unrealistic because we have assumed that all members within each
of the two study populations (cases and controls) have exactly the
same fraction of ancestry coming from the two differing ancestral
groups: a1 from population 1 for the cases and a2 from population
1 for the controls. This is not what is seen in most complex
population groups today, and is not what we see in the AABC data
considered below. Instead in modern admixed populations there is
a relatively wide range of within-population admixture
proportions. If there is overlap due to ancestry for cases and
controls then tests like the Bourgain test, principal components,
multidimensional scaling [22], and genomic matching [23,24]
have a much greater likelihood of success than in the previous
examples. Again we use the Bourgain test to quantify this. For
example we can assume a distribution of values of the admixture
fraction in the case and control samples while keeping a difference
‘‘on average’’ in ancestry between the two groups. We then can
calculate ‘‘appropriate’’ values of the matrix K and use this in
additional calculations. For our purposes the beta distribution
provides a reasonably flexible model for the distribution of
individual values of the admixture proportion in a modern day
admixed population. Figure 1 gives a plot of the density function
for a number of beta distributions. The beta distribution is usually
described in terms of two parameters, r and s with the mean of the
beta distribution equal to
r
rzs
and the variance equal to
rs
(rzs)
2(rzsz1)
. For convenience we re-parameterize this
distribution in terms of its mean, a~
r
rzs
, and a heterogeneity
parameter, h, with r~a=h, so that s~(1{a)=h. Thus samples
from this distribution have mean a and variance a 1{a ðÞ
h
hz1
.
This parameterization is useful when comparing the overlap of
two beta distributions with different means but similar within
group variances as in Figure 1.
We consider now the non-centrality parameter for the Bourgain
test when two incompletely admixed populations are used as cases
and controls where there is an overall difference in admixture
fraction in the two populations but where each population is
heterogeneous with respect to the fraction of ancestry from the two
mixing populations. Figure 2 plots the non-centrality parameter
(NCP) for the Bourgain test against the number, N, of cases and
controls (1:1 case-control ratio for N pairs) for the example used
above (a risk variant of frequency 40 percent overall, and a OR for
disease equal to 1.5 per copy) it is clear from the figure that the
non-centrality parameter is very much determined by the degree
of heterogeneity in admixture percentage within each population
(cases versus controls) as parameterized here by h.
AABC Study Results
Our analysis focuses upon (1) estimating a more appropriate
model for the distribution of ancestry in the data from the AABC
data than the homogeneous ‘‘complete’’ admixture described
above, (2) checking the adequacy of this model, enriching it if
necessary, and (3) describing the implications of the model for the
likely power to detect associations in studies in which all cases
come from outside the AABC study populations, and controls are
chosen from within the AABC. We can partly mimic such studies
by making up ‘‘pseudo’’ case-control studies using the data from
the different study sites within the AABC study.
Principal components analysis of the AABC study. We
used the EIGENSTRAT program to calculate the eigenvectors and
eigenvalues of the matrix ^ K K given in expression (3) using the set of
2,457 AIMs described above. We first noted that the first eigenvalue
of ^ K K was much larger than the remaining eigenvalues (504.85
compared to 29.71 for the next largest). We strongly suspected that
the eigenvector associated with this eigenvalue corresponds to the
fraction of European ancestry based on CEU of HapMap. To clarify
this we ran the program STRUCTURE on AABC study data and
included HapMap genotype data (CEU, YRI, and CBT+YRI) for
these same AIMs. The first eigenvector of the AABC data was highly
correlated (r=0.991) with the estimate of STRUCTURE for the
percentage of European ancestry. For illustrative purposes we added
the HapMap subject’s data to the EIGENSTRAT analysis and
plotted the first 4 eigenvectors in Figure 3.
Variation among AABC study sites in admixture
percentage. Figure 4 shows box plots of the STRUCTURE
estimates of the fraction of European ancestry according to AABC
study site. For each study site, we estimated the mean and variance of
the distribution and related those by the method of moments to the two
parameters (a and h) in our parameterization described above. The
estimate a of average European ancestry varied significantly by study,
from approximately 0.25 for the MEC cohort and other studies in
California to approximately 0.19 for the CBCS and other studies in the
East and South-east United States. The heterogeneity parameter also
varied by site but was generally estimated to be close to 1/7 for all sites,
which indicated a large degree of overlap between the admixture
fractions even between the most different studies.
Other population structure in the AABC study. If the only
ancestry differences among the control populations sampled by the
AABC study relates to fraction of European versus African ancestry
then our previous analysis would indicate that very little loss of
power, compared to using perfectly matched controls, would result
from a case-controlstudy that uses African American cases, and one
(or all) of the AABC control samples as convenience controls, after
adjustment for differences in European versus African ancestry.
Figure 3 gives evidence for some degree of admixture with an Asian
as well as European group, which we assume [10] is largely due to
admixture with Native American or Hispanic populations. The
requirement of controlling for this additional admixture will also
affect the power of using the AABC study as a source of shared
controls, as would other types of admixture or population
stratification. In order to quantify the total effect of the significant
eigenvectors in the AABC data we did the following: Using the
Tracy-Widom statistic as incorporated into EIGENSTRAT we
estimated the number of ‘‘significant’’ eigenvalues (i.e. those
significantly larger than the remaining eigenvalues) and hence the
‘‘significant’’ eigenvectors. Using these significant eigenvectors we
formed a ‘‘smoothed’’ version of the matrix K as
K
_
~
X ‘
i~1
(wi{e)ViVi
TzeI ð7Þ
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1
Ntot{‘
X Ntot
‘z1
wi.H e r e‘ is the number of significant
eigenvectors of ^ K K, the Vi, are the eigenvectors and wi is the
associated eigenvalue. Formula (7) gives a full rank estimate
which has the same first ‘ eigenvectors and eigenvalues as ^ K K as
well as the same trace (sum of all N eigenvalues). We use this to
estimate non-centrality parameters for several example studies,
Figure 1. Plot of the density function of beta distributions parameterized by mean a and heterogeneity factor h. On each subplot the
density is shown for two choices of a namely a=0.2 (solid line) and a=0.25 (dotted lines).
doi:10.1371/journal.pgen.1001096.g001
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200 eigenvalues were nominally significant (at a 5 percent type I
error rate) using the Tracy-Widom statistic and considered the
effect of adjusting for a range of 1 to all 200 eigenvectors in our
calculations. Fewer than all 200 eigenvectors likely to needed in a
realistic analysis, here we are examining an extreme case. The
fact that this many eigenvectors are nominally significant may be
due in part to not controlling for multiple comparisons or may
also be reflective of unsuspected close or distant relatedness
between certain participants.
Specifically we considered a breast cancer study in which all
African-American cases (n1 =635) came from the CBCS and all
controls (n0 =990) came from the Los Angeles component of the
MEC. Accordingly we extracted the 1625 by 1625 submatrix
(corresponding to these selected cases and controls) of K
_
for use in
the calculation of noncentrality parameters. The basic idea is to
Figure 2. Plot of non-centrality parameter for the Bourgain test for a case-control study using two incompletely admixed
populations as sources of cases and controls respectively. The parameters chosen refer to a test of a variant associated with disease which
has 40 percent overall allele frequency and which is associated with a 10 percent difference in frequency between cases and controls (OR=1.5 per
copy). Cases are assumed to have average admixture percentage of 20 percent and controls 25 percent. The within population heterogeneity is
specified by a single common heterogeneity parameter h as used in Figure 1.
doi:10.1371/journal.pgen.1001096.g002
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a study of the same size but where cases and controls are sampled
from the same non-admixed population. Because the appropriate K
and s2
j is not known, but is estimated from the data, our analysis of
power becomes slightly more complicated than above. For a given
SNP, j, we estimated the variance of ^ b b2 by the scalar
½1=(N{2) S
T
j K
_{1{K
_{1C(C
TK
_{1C)
{1C
TK
_{1
hi
Sj|(C
TK
_{1C){1
½2,2  ð8Þ
The expected value of this variance estimate can be written as
tracef½1=(N{2)  K
_{1 {K
_{1C(C
TK
_{1C)
{1C
TK
_{1
hi
E(SjS
T
j )g |(C
TK
_{1C){1
½2,2  ð9Þ
The expected value E(SjS
T
j ) depends upon the details of admixture
and other types of population structure in this subset of AABC
participants and can be written as
Figure 3. Principal components plots of AABC and selected HapMap samples.
doi:10.1371/journal.pgen.1001096.g003
ð8Þ
ð9Þ
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T
j )~mjmT
j zs2
j K: ð10Þ
In a study of homogeneous non-admixed case and control
populations, and under the null hypothesis that b2 is zero, this
reduces to 4pj
211Tz2pj(1{pj)I where pj is the allele frequency of
marker j. Substituting expression (10) into expression (9) with either
K=I (for a homogeneous study) or for K~~ K K (for our example)
allows us to compare the variance of the estimators when a total of ‘
eigenvectors areadjustedforinourhypothesized case-controlstudy,
compared to the homogeneous study. Figure 5 plots the values of
expression (9) for varying values of ‘ for a marker with frequency 20
percent. It appears that correcting for increasing numbers of
eigenvectors (at least beyond the first two components) has relatively
little effect on Var(^ b b2) and hence on study effective sample size and
power. Even using all 200 ‘‘significant’’ eigenvectors in the
calculation of the smoothed estimator K
_
only increases the variance
of the estimator by about 7 percent relative to a study that needs no
correction. Of course we also need to confirm that the false positive
rate for the Bourgain test is properly controlled for by using a
particular number, ‘, of eigenvectors. Figure 6 gives a quantile-
quantile (QQ) plot of the ({log10) p-values from tests of
association of each of the AIMs used to estimate K with case-
control status in our hypothesized study, while using either 0
(uncorrected), 1 (the CEU – YRI component), 10, or 200
eigenvectors to form K
_
. Here the uncorrected analysis is very
highly over-dispersed with a very large number of associations
globally significant (using the Bonferonni test). However even
using just 1 eigenvector appears to give a reasonably adequate
control of the type I error while correcting for 200 gives nearly
perfect control, with little loss of additional power (as indicated in
Figure 5).
Discussion
We have adopted a somewhat non-standard approach in relying
upon the Bourgain test rather than principal components [8] or
related methods [22–24] to control for population structure in a
GWAS of a minority population with cases/controls drawn from
multiple studies with different designs and recruitment approach-
es. We have done this mainly because we can give certain
theoretical results for the Bourgain test when assuming specific
forms for the true kinship matrix K using this procedure. It is
worth noting that the Bourgain test can be regarded as a random
Figure 4. Plot of estimate of proportion of African ancestry from STRUCTURE by participating AABC study.
doi:10.1371/journal.pgen.1001096.g004
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particular the Bourgain model can be alternatively described as a
model for the mean of Sj conditional upon all Ntot eigenvectors of
K as
mj~Cbjzcj,1V1zcj,2V2z   cj,NtotVNtot ð10Þ
Now consider the coefficients cj,1 ...cj,N as being independent
random effects with mean zero and variances equal to sj
2 times
the associated eigenvalues, w1 ...wN of K. Averaging over all the
random cj,i will yield the unconditional mean Cbj and variance
covariance matrix s2
j K. Our ‘‘smoothed’’ estimate, ^ K K,o fK is
motivated by expression (10), and choosing a value of ‘ is
analogous to choosing the number of eigenvectors to be used as
fixed effects by EIGENSTRAT. The random effects framework
also highlights the relationship between the Bourgain procedure
and the genomic control method of Devlin and Roeder [25]. In
genomic control one additional parameter that governs the
dispersion of the test statistic is used to assess the association
between Sj and case-control status. In the smoothed version of the
Bourgain test introduced here, we choose a total of ‘ such
parameters.
We have shown that if cases and controls come from genetically
distinct populations but ones that have only recently diverged (so
that the parameter F is very small) then some limited power
remains to detect true marker associations so long as the true value
of b2 is very large compared to the ‘‘typical’’ differences between
cases and controls seen with the other markers. This is also
analogous in interpretation to the genomic control method.
However our explicit description of the upper bound on the
noncentrality parameter of the association test for such a study
clearly shows the limits of this design, and by implication, the
Figure 5. Plot of variance. Plot of the variance of ^ b b2 according to the
number, ‘, of eigenvectors adjusted for in the Bourgain test of
association.
doi:10.1371/journal.pgen.1001096.g005
Figure 6. Quantile-quantile plot of p-values from association tests in the hypothesized case-control study in which cases from the
CBCS and controls from the MEC are used. The plotted values indicate adjustment for 0 (uncorrected heavy solid line), 1 (dashed line), 10
(dotted line) and 200 (thin solid line) eigenvectors, by using these components in the calculation of K
_
.
doi:10.1371/journal.pgen.1001096.g006
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these two methods behaves ‘‘properly’’ from a statistical point of
view as sample size increases, i.e. the non-centrality parameter
under an alternative hypothesis (and hence power) does not
increase correspondingly. In genomic control the overdispersion
parameter that the procedure corrects for increases with sample
size, while for the Bourgain test the noncentrality parameter is
bounded from above.
For case-control studies involving two or more similarly
admixed populations that differ in admixture fraction, the key
issue in assessing the power of a study using cases from one
population and controls from another is in determining the within-
population heterogeneity of the admixture fractions, relative to the
between population differences in average admixture. If the
within-population heterogeneity is small then the situation is
equivalent to the case of isolated populations, i.e., there will be a
bound on the power of a study to detect an effect with the bound
determined by the upper limit on the noncentrality parameter as a
function of N as computed above.
Despite the concerns raised in our theoretical considerations, in
our assessment of the observed marker data from the AABC study
we tentatively conclude that reuse of controls data from this study
in future work may be statistically feasible. While there are clear
differences in average admixture fraction between studies these are
dwarfed by the within-study heterogeneity. Other signs of hidden
structure in the AABC studies (as evidenced by additional
eigenvalues which are significant by the Tracy-Widom test) do
not appear to have a very large impact (Figure 5) on the power of
our hypothetical study using the CBCS and MEC cases and
controls respectively. Control for the first few (1–200 in our case)
eigenvectors appears to dramatically reduce false positive
associations with very little power loss (about a 7 percent reduction
in effective sample size) relative to studies of homogeneous sets of
cases and controls. We have used a specific set of ancestry
informative markers in our analysis but the existence of genome-
wide data for the AABC allows for considerable latitude in
selecting SNPs to control for admixture, and even randomly
selected SNPs, if enough are considered, can be used for
admixture correction. Our use of the Bourgain test when
considering the feasibility of a particular study design allows us
to consider noncentrality parameters (and hence power) in
particularly simple and helpful ways. While we have focused on
the Bourgain method to correct for admixture differences in the
AABC study our specific finding (that little loss in power is
anticipated when re-using control data from this study) is likely to
apply also to fixed-effects methods such as treating principal
components or STRUCTURE estimates of percentage ancestry
from ancestral populations as covariates. Our reasoning is based
upon the close relationship between the principal components
methods and the random effects rationale for the Bourgain test as
given in equation (10) and also on the high correlation seen
between STRUCTURE estimates of African ancestry in the
AABC study and the first eigenvector from principal components.
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